Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 4/20 | 0.76 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.76 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.76 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | DGKA | P23743 | 1/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1924789 | 0.98 | PRKCA (0.79) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL237351 | 0.98 | PRKCA (0.79) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL15011314 | 0.98 | PRKCA (0.79) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL528141 | 0.98 | PRKCA (0.79) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL528434 | 0.89 | PRKCA (0.82) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL593855 | 0.88 | PRKCA (0.97) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL2195274 | 0.88 | PRKCA (0.97) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL426747 | 0.87 | PRKCA (0.57) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL23668326 | 0.86 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL7061646 | 0.86 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043402-A1 | Methods and formulations for counteracting infection of mucosa or skin | LIPOMEDICA EHF. (IS) | 2005-02-24 | — | — | US | disclosed |
| US-6596763-B1 | Method for counteracting infections caused by bacteria, fungi or virus such as Herpes Simplex Virus in skin or mucosal membranes, in particular genital membranes, of a mammal. The method comprises topically administering to skin or mucous | LIPOMEDICA EHF. (IS) | 2003-07-22 | — | — | US | disclosed |
| EP-0941087-A1 | TOPICAL FORMULATIONS CONTAINING AS A THERAPEUTIC ACTIVE AGENT FATTY ACIDS OR FATTY ALCOHOLS OR MONOGLYCERIDE DERIVATIVES THEREOF FOR TREATING OF MUCOSA INFECTIONS | Thormar, Halldor (IS) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998020872-A1 | TOPICAL FORMULATIONS CONTAINING AS A THERAPEUTIC ACTIVE AGENT FATTY ACIDS OR FATTY ALCOHOLS OR MONOGLYCERIDE DERIVATIVES THEREOF FOR TREATING OF MUCOSA INFECTIONS | THORMAR HALLDOR (IS) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043402-A1 | Methods and formulations for counteracting infection of mucosa or skin | MGLL, GK, UGCG | PRKCA 2219/4885PRKCE 1895/4885PRKCQ 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.